A study has revealed that fondaparinux, a synthetic inhibitor of coagulation factor Xa, is a promising treatment option for patients with acute coronary syndromes. Mehta et al. performed a ...

Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...

Fondaparinux sodium is a newer synthetic anticoagulant that is used for both VTE treatment and prophylaxis. It is predominantly excreted unchanged in the urine and has a half-life of 17–21 hours ...

Published trials used fondaparinux sodium 2.5 mg daily for venous thromboembolism prophylaxis in surgical patients, and the majority avoided its use before surgery in patients receiving neuraxial ...